Fall 2026
Quality Assurance Apprentice
Revvity
1,001-5,000 employees
Translational multi-omics and diagnostics provider
Compensation Overview
£103.85/hr
Llantrisant, Pontyclun, UK
In Person
Occasional domestic and international travel is required, with day-release travel to the Swansea campus.
Bachelor's
 QA & Testing (1) |
|---|
Get referred to Revvity
See people who can refer or advise you
- Good communication skills to interact successfully with team leaders, fellow engineers, Quality Assurance personnel, and management.
- A self-motivated approach to keeping up with university work alongside daily activities.
- A proactive approach to identifying and resolving problems.
- Willingness to work within a structured development program and take responsibility for personal development.
- Ability to critically assess performance and engineering practices to define and improve departmental procedures.
- Minimum GCSE grade C, including Mathematics, English, Science, and other relevant subjects such as Engineering or Product Design.
- A levels at grade BCC, including Mathematics and a Science subject.
- Experience using Microsoft Word, Excel, PowerPoint, and Outlook.
- A self-motivated, detail-oriented, practical mindset and passion for learning.
- Good organizational skills.
- Work alongside Quality Technicians and Engineers.
- Support process and quality audits.
- Work with members of the manufacturing engineering team to investigate improvements following field failures and Voice of the Customer reports.
- Evaluate failure trends and capability data to support improvement projects.
- Take an active role in delivering New Product Introductions.
- Participate in Continuous Improvement activities by suggesting and delivering improvements through a structured, project-based approach.
- Attend the University of Wales Trinity Saint David one or two days per week on a day-release basis to study engineering management.
- Travel to the University of Wales Trinity Saint David Swansea campus on day release.
- Undertake occasional domestic and international travel.
Revvity provides health science solutions that span the full journey from discovery to development and from diagnosis to cure. It offers translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection, diagnosis, and informatics, all delivered as integrated workflows and expert services. The company differentiates itself with an end-to-end platform that combines omics, imaging, biomarkers, and data analytics with specialized support to speed development. Its goal is to turn previously impossible healthcare outcomes into achievable results, advancing discovery, development, diagnosis and patient care.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Waltham, Massachusetts
Founded
2023
Get referred to Revvity
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 revenue reached $730 million, with 3% organic growth and raised guidance.
- Signals for Startups launched July 2026, opening enterprise software sales to seed-stage biotechs.
- SuperFlex and T-SPOT A201 expand Revvity's menu into prenatal and infectious-disease testing.
What critics are saying
- China Immunodiagnostics was 6% of 2025 revenue; divestiture closes only by end-2027.
- T-SPOT A201 still needs regulatory approval and a second-half 2027 launch.
- Diagnostics growth slowed to 3% organic in Q2 2026, leaving Revvity dependent on execution.
What makes Revvity unique
- Revvity owns both diagnostics and Signals software, spanning discovery, screening, and clinical workflows.
- SuperFlex targets lower-volume labs with CE-IVDR automation, filling a neglected prenatal screening niche.
- T-SPOT A201 extends Revvity's proprietary latent TB franchise into high-throughput automation.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Company Match
Employee Stock Purchase Plan
Growth & Insights and Company News
6 month growth
↑ 5%1 year growth
↑ 5%2 year growth
↑ 4%Revvity has launched SuperFlex, a compact prenatal screening system designed for small and mid-sized laboratories. The CE-IVDR-certified automated immunoassay instrument will initially be available in markets accepting CE-marked instruments, with Asia-Pacific expansion planned for late 2026. The benchtop immunoanalyser processes up to 60 tests per hour and delivers initial results in 14 minutes. It supports preeclampsia screening and prenatal testing using chemiluminescence immunoassay technology with 24 sample positions. SuperFlex aims to address financial and operational barriers in lower-volume testing environments by offering lower instrument costs, reduced maintenance expenses, and no reagent wastage. The platform integrates with Revvity's LifeCycle software. Revvity shares gained 1.6% following the announcement and have risen 21.8% year-to-date. The company has a market capitalisation of $12.91 billion.
Revvity has launched the SuperFlex prenatal screening system, a compact, CE-IVDR certified immunoassay instrument designed for laboratories and clinics with lower-volume workflows. The system tests for preeclampsia, which affects 2% to 8% of pregnancies globally. The platform features affordable instrument costs with annual maintenance, no reagent wastage at low volumes, and delivers results in as little as 14 minutes per test. It includes a test menu for first- and second-trimester biochemical prenatal screening. The system will initially be available in markets accepting CE-marked instruments, with Asia-Pacific expansion planned for late 2026. Revvity reported 2025 revenue of $2.9 billion and employs approximately 11,000 people.
Upstart, an AI-powered lending platform, stands out as a buy opportunity among profitable stocks, according to StockStory's analysis. The company uses machine learning to assess borrower risk for various loan types. Upstart's loan originations surged 54.3% over the past year, enabling increased fee collection and expansion into new markets like credit cards. The company's revenue is expected to grow 30.6% over the next 12 months, with free cash flow anticipated to turn positive next year. Meanwhile, StockStory advises caution on Revvity and Northern Trust. Revvity's sales declined 10.6% annually over five years, whilst Northern Trust's 6.9% annual revenue growth lagged behind financial peers. Both companies face headwinds despite maintaining profitability, with earnings pressures and market share concerns affecting their outlooks.
Revvity reported second quarter 2026 revenue of $730 million, with pro forma revenue of $711 million representing 4% growth and 3% organic growth. The company posted GAAP earnings per share from continuing operations of $0.48, while adjusted EPS reached $1.41. The company announced a definitive agreement to divest its China Immunodiagnostics business, which accounted for approximately 6% of total revenue in fiscal year 2025. The transaction is expected to close by the end of 2027, subject to regulatory approvals. Adjusted operating profit margin improved to 28.9%, up from 26.6% in the prior year period. GAAP operating income included $16 million in tariff-related refunds. Revvity raised its full-year guidance following the results.
A meaningful gift marks a milestone moment at Rompa CZ. Rompa now has a lasting reminder of the opening ceremony for its new Class 7 cleanroom facility in the Czech Republic, in the form of a thoughtful symbolic gift from its customer, the biotechnology company Revvity. This special artwork connects the event to the wider story of Life Sciences research, and was presented by Revvity's Managing Director, Jochem Bruggeman, to Marcos Valladolid, Rompa's COO. The story behind the artwork. The art was created using Revvity's own instruments and depicts HeLa cells, which hold a unique place in biomedical research. They were the first human cells successfully grown continuously in a laboratory and remain one of the most widely used cell lines in science today. Originally taken from Henrietta Lacks in 1951, HeLa cells have contributed to thousands of scientific breakthroughs over more than 75 years of research. They have played an important role in areas including vaccine development, cancer research, virology, drug screening, gene mapping and many other fields of biomedical science. The story of HeLa cells is also an important reminder of the ethical responsibilities that come with scientific progress. Henrietta Lacks' cells were used without her knowledge or consent, raising questions about patient rights, informed consent and the use of biological materials in research. Those discussions continue to influence how biomedical research is conducted today. Celebrating a long-standing partnership with Revvity. For Rompa, the present is a symbol of the partnership between its two companies and of the Life Sciences work now taking place inside the new cleanroom. The gift also marks Rompa's longstanding partnership with Revvity, whose products are among the first being produced in the new ISO Class 7 cleanroom at Rompa CZ. This made the opening ceremony not only a celebration of a new facility, but also a celebration of the collaboration, trust and shared commitment that helped bring the project to life. The cleanroom is designed to support multiple integrated production lines, including automated manufacturing solutions for microplate production. It enables Rompa to support customers with demanding applications in healthcare, diagnostics and other highly regulated Life Sciences markets. Rompa Group is grateful to Revvity for such a thoughtful gesture, and to everyone who joined Rompa Group to mark this important moment for Rompa CZ. As the artwork reminds Rompa Group, progress in Life Sciences depends on precision, partnership and respect for the scientific work that helps improve lives. Rompa Group is proud that its new cleanroom will play a part in supporting that work for years to come.